重症监护中去甲肾上腺素制剂报告:美国重症医学会与欧洲重症医学会联合工作组立场声明
该立场声明由美国重症医学会与欧洲重症医学会联合工作组制定,工作组于2023年8月至10月召开系列电话会议并复习现有证据。文件检视了去甲肾上腺素以共轭盐(重酒石酸盐或酒石酸盐)或碱基形式标示对有效浓度的影响,指出这些差异对临床用药、临床试验入组剂量计算以及报告最大去甲肾上腺素等效剂量的数据集结果均有显著影响,在跨国协作场景中尤为重要。工作组倡导全球统一采用去甲肾上腺素碱基制剂,并针对各相关方提出建议。
要点
- 去甲肾上腺素以共轭盐(重酒石酸盐或酒石酸盐)或碱基标示,有效浓度存在差异,影响临床用药与剂量计算。
- 该差异对临床试验入组剂量计算及报告最大去甲肾上腺素等效剂量的数据集结果有显著影响。
- 在跨国协作研究中,制剂标示差异尤为重要,可导致报告结果不可比。
- 联合工作组倡导全球统一使用以去甲肾上腺素碱基标示的制剂。
- 工作组针对各相关方提出了相应建议。
适用人群与场景
- 参与重症监护实践、研究及数据报告的临床医生、研究者与相关方,涉及跨国协作场景。
研究设计与关键结果
- 该文件为美国重症医学会与欧洲重症医学会联合工作组立场声明,工作组于2023年8月至2023年10月召开系列电话会议并复习现有证据与问题范围。
- 文件检视了去甲肾上腺素以共轭盐(重酒石酸盐或酒石酸盐)或碱基标示时对有效浓度的影响。
- 这些差异对临床用药、临床试验入组剂量计算以及报告最大去甲肾上腺素等效剂量的数据集结果均有显著影响。
- 这些差异在跨国协作、各国报告存在差异的场景中尤为重要。
- 工作组倡导全球统一使用以去甲肾上腺素碱基标示的制剂,并针对各相关方提出建议。
证据类型、等级与局限
- 证据类型:美国重症医学会与欧洲重症医学会联合工作组立场声明,基于系列电话会议与现有证据复习。
- 局限:原文未报告局限性
对床旁实践的改变
- 工作组倡导全球统一使用以去甲肾上腺素碱基标示的制剂,以避免盐型与碱基标示差异带来的用药、剂量计算与研究数据报告问题。
- 作者认为应关注去甲肾上腺素制剂标示差异对临床试验入组剂量计算及最大去甲肾上腺素等效剂量数据集结果的影响,尤其在跨国协作场景中。
指南或共识出处
- 美国重症医学会与欧洲重症医学会联合工作组立场声明:重症监护中去甲肾上腺素制剂报告(Position Paper on the Reporting of Norepinephrine Formulations in Critical Care),发表于 Critical Care Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To provide guidance on the reporting of norepinephrine formulation labeling, reporting in publications, and use in clinical practice.
DESIGN: Review and task force position statements with necessary guidance.
SETTING: A series of group conference calls were conducted from August 2023 to October 2023, along with a review of the available evidence and scope of the problem.
SUBJECTS: A task force of multinational and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine.
INTERVENTIONS: The implications of a variation in norepinephrine labeled as conjugated salt (i.e., bitartrate or tartrate) or base drug in terms of effective concentration of norepinephrine were examined, and guidance was provided.
MEASUREMENTS AND MAIN RESULTS: There were significant implications for clinical care, dose calculations for enrollment in clinical trials, and results of datasets reporting maximal norepinephrine equivalents. These differences were especially important in the setting of collaborative efforts across countries with reported differences.
CONCLUSIONS: A joint task force position statement was created outlining the scope of norepinephrine-dose formulation variations, and implications for research, patient safety, and clinical care. The task force advocated for a uniform norepinephrine-base formulation for global use, and offered advice aimed at appropriate stakeholders.
参考来源
- Wieruszewski PM, Leone M, Kaas-Hansen BS, et al. Position Paper on the Reporting of Norepinephrine Formulations in Critical Care from the Society of Critical Care Medicine and European Society of Intensive Care Medicine Joint Task Force. Crit Care Med. 2024. PMID: 38240498. doi:10.1097/CCM.0000000000006176
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。